TAK-169 Represents a Novel Mechanism of Action Targeting CD38 Phase I Study to be Conducted in Relapsed/Refractory Multiple Myeloma Patients AUSTIN, Texas , June 17, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”) a clinical stage
AUSTIN, Texas , May 14, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
AUSTIN, Texas , May 13, 2019 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,
Dosing in Phase I Study in Patients with HER2-Positive Cancers Expected to Start in 3Q19 AUSTIN, Texas , April 22, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies
Presentations from multiple pipeline programs feature data demonstrating continued evidence of forced internalization with CD38 and PD-L1 leads, dramatically improved tolerability in NHP models, enhanced potency, and weekly or bi-weekly dosing with TAK-169 AUSTIN, Texas , April 02, 2019 (GLOBE
AUSTIN, Texas , March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,
Study Update Expected in 2H19 with Final Data Expected in 2020 AUSTIN, Texas , March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted
AUSTIN, Texas , March 05, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
Presentations will feature data on 1) CD38-targeted ETB TAK-169, 2) CD20-targeted ETB MT-3724 in combination with chemotherapy or IMiDs, 3) PD-L1-targeted ETB for direct cell kill approach to PD-L1 expressing cancers, 4) Bispecific ETBs for targeted cancer treatment AUSTIN, Texas , Feb.
AUSTIN, Texas , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,
